Summary
Edvara and ICON are collaborating to develop AI agents and tools aimed at reducing administrative burdens in the clinical trial ecosystem, particularly at research sites. This partnership emphasizes the importance of a connected ecosystem rather than relying on a single universal platform. By enhancing interoperability and site efficiency, the collaboration seeks to allow clinical sites to focus more on patient care rather than administrative tasks.
The discussion highlights the challenges of ensuring effective communication and governance between various systems and organizations involved in clinical trials. Both companies recognize the need for agents to operate within defined parameters, ensuring that human oversight remains integral, especially in high-stakes areas like trial design and patient safety. The goal is to create a more efficient process that enables sites to conduct more research while minimizing the complexities that often accompany clinical trials.
Looking ahead, the partnership aims to streamline site activation processes and improve overall research capacity. By leveraging AI technology, they hope to facilitate better communication between agents across different platforms, ultimately enhancing the experience for both sites and patients. The emphasis remains on building smart partnerships and focusing on niche solutions that cater to the specific needs of the clinical research ecosystem.
Show Notes
Collaboration is at the core of connecting the clinical research ecosystem without adding to the technology burden for sites. The ongoing partnership between Advarra and ICON offers a practical example of what this can look like.In Good Clinical Podcast Season 5, Episode 3, Mike Eckrote (Advarra) and Travis Caudill (ICON) discuss how their collaboration is helping move toward an ecosystem where organizations and sites can continue using the tools that best meet their needs, while enabling information to flow seamlessly across systems and organizational boundaries.They explore the potential to reduce administrative complexity, improve interoperability, strengthen site efficiency, and keep humans at the center of critical decisions, ultimately creating more time and capacity for what matters most: patients.
More from ACRO's Good Clinical Podcast
What does the future of early-stage clinical research look like?In this episode, experts from clinical operations, IRB/regulatory oversight, and technology/policy — Amy Roach (Parexel), Bert Wilkins (WCG), and Jackie Ward (Veeva) — explore the evolving landscape of early-stage clinical trials in the U.S. From regulatory modernization and global competitiveness to interoperability, participant access, and increasingly complex trial designs, the discussion centers on how the U.S. can improve speed, efficiency, and predictability while preserving safety, rigor, and quality.
AI is transforming trial monitoring from a reactive process into a proactive, risk-driven discipline. In this episode, ACRO RBQM Working Group members Cris McDavid (Parexel), Shailesh Madel (ICON), and Linda Phillips (IQVIA), come together to examine how artificial intelligence and machine learning can help identify risks and signals faster while humans maintain accountability and oversight.From accelerating the identification of Critical-to-Quality (CtQ) factors and enhancing centralized monitoring to addressing concerns around pushing humans out of the loop, the discussion highlights both the challenges and opportunities ahead. With insights on how AI is already being leveraged to increase operational efficiencies while balancing patient safety and data integrity, this episode offers a glimpse into the future of centralized monitoring.
In this episode of ACRO's GCP, Tinaya Gray (Executive Director, Site Engagement & PACE at ICON plc), Jan Hewett (SVP, FDA Regulatory Advisor at Advarra), and Jackie Kent (Independent Advisor) unpack the work of ACRO's dive team on representative, generalizable clinical trial data at the 2025 Innovation Network Gathering. Together, they explore why clinical trial populations still fail to reflect real-world patients, and what's been holding the industry back from meaningful progress.The conversation goes beyond identifying the problem. The group shares how a diverse set of stakeholders were able to align around practical, implementable solutions. They also discuss how industry can pilot new approaches, engage broader stakeholders, and turn promising ideas into standard practice. This episode offers a candid and solutions-oriented look at how to generate clinical data that truly supports better decision-making for all patients.
Artificial intelligence is reshaping clinical research, but its impact extends far beyond automation. In this episode of ACRO’s Good Clinical Podcast, host Sophia McLeod is joined by Paulo Limgenco (VP, Business Operations at YPrime) and Michael Tucker (VP, Patient Experience - Commercial at Medidata) to explore how AI and digital technologies are helping the industry build more sustainable, efficient, and patient-centered clinical trials.From protocol optimization and site selection to localization and decentralized trial models, the conversation examines how AI can reduce operational burdens, minimize waste, and expand access to research opportunities for underrepresented populations. The discussion also highlights the importance of responsible AI adoption, including strong governance frameworks, data stewardship, and human oversight.Tune in for an insightful conversation on how the industry is balancing innovation and responsibility while working toward a future where clinical trials are more efficient, inclusive, and sustainable for patients, sites, sponsors, and communities worldwide.
What does it take to run successful clinical trials across borders? Tune in as Chris Boone (Group VP, Research, Health & Life Sciences at Oracle) and Alicia Baker McDowell (VP & Head of Global Regulatory Strategy at Fortrea) explore the shift from transactional outsourcing to truly co-created partnerships.They discuss how sponsors, CROs, and tech partners are redefining collaboration, tackling data fragmentation, and striking the right balance between global consistency and local execution to deliver more effective clinical trials worldwide.